Summary & Overview
CPT 90733: Quadrivalent Meningococcal Polysaccharide Vaccine, Subcutaneous
CPT code 90733 designates the provider administration of a quadrivalent meningococcal polysaccharide vaccine given subcutaneously to protect against four meningococcal strains. This immunization code is used across outpatient and community vaccination settings and is clinically important for preventing invasive meningococcal disease in eligible populations. Nationally, consistent coding supports public health reporting, vaccine coverage measurement, and appropriate billing for preventive services.
Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of how 90733 is characterized in billing workflows, standard service contexts, and payer coverage considerations. The publication provides benchmarks and policy context relevant to vaccine administration codes, highlights common documentation practices, and summarizes clinical context for use of quadrivalent meningococcal polysaccharide vaccine.
Where input data are incomplete, the text notes missing items without fabrication. The content is intended for national audiences involved in billing, compliance, and clinical program planning for immunization services.
Billing Code Overview
CPT code 90733 describes administration of a quadrivalent meningococcal polysaccharide vaccine, subcutaneous, intended to protect against four strains of Neisseria meningitidis that cause meningitis. The entry documents the vaccine administration procedure performed by a provider.
-
Service type: Vaccine administration
-
Typical site of service: Ambulatory care settings such as physician offices, clinics, and public health or community vaccination sites
Clinical & Coding Specifications
Clinical Context
A healthy adolescent or young adult presents to a primary care clinic or public health immunization site for routine vaccination prior to travel, school entry, or military enlistment. The clinical workflow includes verification of immunization history, screening for contraindications (severe allergic reaction to prior meningococcal vaccine or vaccine component), informed consent, documentation of date/site/lot/manufacturer, and administration of the quadrivalent meningococcal polysaccharide vaccine subcutaneously. Observation for immediate adverse reaction (typically 15 minutes) follows, with provision of vaccine information statement and scheduling of follow-up doses if indicated. Billing is submitted using 90733 for the vaccine administration; the typical site of service is an outpatient clinic, public health clinic, or travel clinic.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — standard; used when no other modifier applies | Rarely appended; billing systems may default to no modifier for routine immunization |
| 11 | Office or other outpatient visit | When the vaccine is administered as part of an evaluated outpatient visit and payer requires this modifier to denote an outpatient setting